Loading...
Loading...
BCTX| Name | Value |
|---|---|
| Revenues | 22.7K |
| Cost of Revenue | 0.0K |
| Gross Profit | 22.7K |
| Operating Expense | 5,768.0K |
| Operating I/L | -5,768.0K |
| Other Income/Expense | 4,749.9K |
| Interest Income | 0.0K |
| Pretax | -1,018.1K |
| Income Tax Expense | 220.4K |
| Net Income/Loss | -1,204.2K |
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company focused on developing immunotherapies for cancer treatment. Its lead candidate, Bria-IMT, is in a Phase I/IIa clinical trial in combination with immune checkpoint inhibitors for breast cancer treatment. The company also collaborates with the National Cancer Institute to develop Bria-OTS, a personalized immunotherapy for advanced breast cancer, and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. generates revenue through the development and potential commercialization of its immunotherapies and diagnostic products for cancer patients.
